Drug treatment before and after surgery for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two targeted drugs, with or without chemotherapy, given before and after surgery for stomach or gastroesophageal junction cancer. It aims to improve the chance of curing the cancer by shrinking it before surgery and controlling any remaining cancer after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach or gastroesophageal junction cancer that can be removed with surgery.
- Your tumor is stage II or III and has not spread to distant organs.
- You have not had prior chemotherapy, radiation, or surgery for this cancer.
- You are in good enough health to undergo surgery after the treatment period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a combination of chemotherapy drugs and an immunotherapy drug given before surgery for stomach cancer in younger patients. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of new drugs given before surgery for stomach or gastroesophageal junction cancer. The goal is to see if it can shrink tumors and improve outcomes for patients whose cancer has certain markers.
This trial tests a new drug combined with chemotherapy before surgery for stomach cancer that has spread to nearby areas. It aims to shrink the tumor to make surgery more successful.
This trial tests two new investigational drugs (SHR-A1811 and SHR-A1701) given before surgery for stomach cancer that is HER2-positive and may respond to immunotherapy. The goal is to see if these drugs can shrink the tumor or improve outcomes when combined with surgery.
Hear when a new Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.